Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
_____________
 
FORM 8-K
_____________
 
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 3, 2008
Date of Report (Date of Earliest Event Reported)
_____________

Neurologix, Inc.
(Exact name of Registrant as Specified in its Charter)

_____________
 
Delaware
000-13347
06-1582875
(State or other Jurisdiction 
(Commission File Number)
(I.R.S. Employer Identification No.)
of Incorporation or Organization)
    
 
 
  

One Bridge Plaza, Fort Lee, New Jersey 07024
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:  (201) 592-6451


(Former Name or Former Address, if changed since last report)
_____________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 1.01 Entry into a Material Definitive Agreement
 
Neurologix, Inc. (the “Company”) entered into a letter agreement (the “Letter Agreement”) dated October 3, 2008 with Dr. Matthew During.  The Letter Agreement amends a Consulting Agreement dated October 1, 1999, as amended (the “Consulting Agreement”), by and between the Company and Dr. During.  The Letter Agreement extends the term of the Consulting Agreement from September 30, 2008, to September 30, 2009.  Dr. During is a co-founder of the Company and a member of its Scientific Advisory Board.
 
A copy of the Letter Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d)           Exhibits

10.1           Letter Agreement dated October 3, 2008 between Neurologix, Inc. and Dr. Matthew During.

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto, duly authorized.
 
 
NEUROLOGIX, INC.
  
       
       
Date: October 7, 2008
By:
/s/ Marc L. Panoff  
  Name:  Marc L. Panoff  
  Title:  Chief Financial Officer, Secretary and Treasurer